294 related articles for article (PubMed ID: 31479461)
1. The molecular determinants of R-roscovitine block of hERG channels.
Cernuda B; Fernandes CT; Allam SM; Orzillo M; Suppa G; Chia Chang Z; Athanasopoulos D; Buraei Z
PLoS One; 2019; 14(9):e0217733. PubMed ID: 31479461
[TBL] [Abstract][Full Text] [Related]
2. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
[TBL] [Abstract][Full Text] [Related]
3. Blockade of the human ether-a-go-go-related gene potassium channel by ketamine.
Zhang P; Xing J; Luo A; Feng J; Liu Z; Gao C; Ma J
J Pharm Pharmacol; 2013 Sep; 65(9):1321-8. PubMed ID: 23927470
[TBL] [Abstract][Full Text] [Related]
4. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
5. Molecular determinants of hERG potassium channel inhibition by disopyramide.
El Harchi A; Zhang YH; Hussein L; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2012 Jan; 52(1):185-95. PubMed ID: 21989164
[TBL] [Abstract][Full Text] [Related]
6. Structural requirements of human ether-a-go-go-related gene channels for block by bupivacaine.
Siebrands CC; Friederich P
Anesthesiology; 2007 Mar; 106(3):523-31. PubMed ID: 17325511
[TBL] [Abstract][Full Text] [Related]
7. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy.
Ganapathi SB; Kester M; Elmslie KS
Am J Physiol Cell Physiol; 2009 Apr; 296(4):C701-10. PubMed ID: 19244476
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant.
Hosaka Y; Iwata M; Kamiya N; Yamada M; Kinoshita K; Fukunishi Y; Tsujimae K; Hibino H; Aizawa Y; Inanobe A; Nakamura H; Kurachi Y
Channels (Austin); 2007; 1(3):198-208. PubMed ID: 18690032
[TBL] [Abstract][Full Text] [Related]
9. Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
Schwoerer AP; Blütner C; Brandt S; Binder S; Siebrands CC; Ehmke H; Friederich P
Anesthesiology; 2007 May; 106(5):967-76. PubMed ID: 17457128
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of hERG channel block by terfenadine and cisapride.
Kamiya K; Niwa R; Morishima M; Honjo H; Sanguinetti MC
J Pharmacol Sci; 2008 Nov; 108(3):301-7. PubMed ID: 18987434
[TBL] [Abstract][Full Text] [Related]
11. Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac hERG potassium channels.
Kiesecker C; Alter M; Kathöfer S; Zitron E; Scholz EP; Thomas D; Kreuzer J; Katus HA; Bauer A; Karle CA
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jun; 373(3):212-20. PubMed ID: 16736158
[TBL] [Abstract][Full Text] [Related]
12. Molecular Determinants for the High-Affinity Blockade of Human Ether-à-go-go-Related Gene K + Channel by Tolterodine.
Wang N; Yang Y; Wen J; Fan XR; Li J; Xiong B; Zhang J; Zeng B; Shen JW; Chen GL
J Cardiovasc Pharmacol; 2022 Nov; 80(5):679-689. PubMed ID: 35881423
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the human ether-a-go-go-related gene potassium channel by ketanserin.
Tu DN; Zou AR; Liao YH; Du YM; Wang XP; Li L
Sheng Li Xue Bao; 2008 Aug; 60(4):525-34. PubMed ID: 18690396
[TBL] [Abstract][Full Text] [Related]
14. Procaine, a state-dependent blocker, inhibits HERG channels by helix residue Y652 and F656 in the S6 transmembrane domain.
Wang N; Ma JH; Zhang PH
J Pharmacol Sci; 2013 Sep; 123(1):25-35. PubMed ID: 24005047
[TBL] [Abstract][Full Text] [Related]
15. Block effect of capsaicin on hERG potassium currents is enhanced by S6 mutation at Y652.
Xing J; Ma J; Zhang P; Fan X
Eur J Pharmacol; 2010 Mar; 630(1-3):1-9. PubMed ID: 19903464
[TBL] [Abstract][Full Text] [Related]
16. Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.
Zhang Y; Colenso CK; El Harchi A; Cheng H; Witchel HJ; Dempsey CE; Hancox JC
Biochem Pharmacol; 2016 Aug; 113():24-35. PubMed ID: 27256139
[TBL] [Abstract][Full Text] [Related]
17. hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.
Melgari D; Brack KE; Zhang C; Zhang Y; El Harchi A; Mitcheson JS; Dempsey CE; Ng GA; Hancox JC
J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25911606
[TBL] [Abstract][Full Text] [Related]
18. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.
Milnes JT; Crociani O; Arcangeli A; Hancox JC; Witchel HJ
Br J Pharmacol; 2003 Jul; 139(5):887-98. PubMed ID: 12839862
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.
Thomas D; Hammerling BC; Wu K; Wimmer AB; Ficker EK; Kirsch GE; Kochan MC; Wible BA; Scholz EP; Zitron E; Kathöfer S; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J
Br J Pharmacol; 2004 Jun; 142(3):485-94. PubMed ID: 15148258
[TBL] [Abstract][Full Text] [Related]
20. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants.
Su Z; Chen J; Martin RL; McDermott JS; Cox BF; Gopalakrishnan M; Gintant GA
Biochem Pharmacol; 2006 Jan; 71(3):278-86. PubMed ID: 16325148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
